Short-Term Treatment with Silymarin Improved 6-OHDA-Induced Catalepsy and Motor Imbalance in Hemi-Parkisonian Rats

Overview

Journal Adv Pharm Bull

Date 2016 Jan 29

PMID 26819917

Citations 8

Authors

Rasool Haddadi

Shahla Eyvari Brooshghalan

Safar Farajniya

Alireza Mohajjel Nayebi

Hamdolah Sharifi

Affiliations

Soon will be listed here.

Abstract

Purpose: Parkinson's disease (PD) is a common neurodegenerative disorder characterized by disabling motor abnormalities, which include tremor, muscle stiffness, paucity of voluntary movements, and postural instability. Silymarin (SM) or milk thistle extract, is known to own antioxidative, anti-apoptotic, anti-inflammatory and neuroprotective effects. In the present study, we investigated the effect of intraperitoneal (i.p) administration of SM, on 6-OHDA-induced motor-impairments (catalepsy and imbalance) in the rats.

Methods: Experimental model of PD was induced by unilateral infusion of 6-hydroxydopamine (6-OHDA; 8 μg/2 μl/rat) into the central region of the substantia nigra pars compacta (SNc). Catalepsy and motor coordination were assessed by using of bar test and rotarod respectively.

Results: The results showed a significant (p<0.001) increase in catalepsy of 6-OHDA-lesioned rats whereas; in SM (100, 200 and 300 mg/kg, i.p for 5 days) treated hemi-parkinsonian rats catalepsy was decreased markedly (p<0.001). Furthermore, there was a significant (p<0.001) increase in motor-imbalance of 6-OHDA-lesioned rats. SM improved motor coordination significantly (p<0.001) in a dose dependent manner and increased motor balance.

Conclusion: In conclusion, we found that short-term treatment with SM could improve 6-OHDA-induced catalepsy and motor imbalance in rats. We suggest that SM can be used as adjunctive therapy along with commonly used anti-parkinsonian drugs. However, further clinical trial studies should be carried out to prove this hypothesis.

Citing Articles

Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer's Disease and Other Neurological Disorders.

Almutary A, Begum M, Siddiqua A, Gupta S, Chauhan P, Wadhwa K Mol Neurobiol. 2025; .

PMID: 39956886 DOI: 10.1007/s12035-024-04654-y.

Deep-Brain Subthalamic Nucleus Stimulation Enhances Food-Related Motivation by Influencing Neuroinflammation and Anxiety Levels in a Rat Model of Early-Stage Parkinson's Disease.

Grembecka B, Majkutewicz I, Harackiewicz O, Wrona D Int J Mol Sci. 2023; 24(23).

PMID: 38069238 PMC: 10706602. DOI: 10.3390/ijms242316916.

Neuroprotective effects of silymarin in 3-nitropropionic acid-induced neurotoxicity in male mice: improving behavioral deficits by attenuating oxidative stress and neuroinflammation.

Haddadi R, Eyvari-Brooshghalan S, Makhdoomi S, Fadaiie A, Komaki A, Daneshvar A Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(4):2447-2463.

PMID: 37847410 DOI: 10.1007/s00210-023-02776-z.

Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight.

Ranjan S, Gautam A Front Neurosci. 2023; 17:1159806.

PMID: 37274201 PMC: 10232807. DOI: 10.3389/fnins.2023.1159806.

Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson's Disease.

Prasad E, Hung S Antioxidants (Basel). 2020; 9(10).

PMID: 33081318 PMC: 7602991. DOI: 10.3390/antiox9101007.

References

Schwarting R, Huston J . The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol. 1996; 50(2-3):275-331. DOI: 10.1016/s0301-0082(96)00040-8. View

Baluchnejadmojarad T, Roghani M, Mafakheri M . Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: involvement of estrogen receptors and oxidative stress. Neurosci Lett. 2010; 480(3):206-10. DOI: 10.1016/j.neulet.2010.06.038. View

Sharifi H, Nayebi A, Farajnia S . 8-OH-DPAT (5-HT1A agonist) Attenuates 6-Hydroxy- dopamine-induced catalepsy and Modulates Inflammatory Cytokines in Rats. Iran J Basic Med Sci. 2014; 16(12):1270-5. PMC: 3933805. View

Jenner P, Olanow C . The pathogenesis of cell death in Parkinson's disease. Neurology. 2006; 66(10 Suppl 4):S24-36. DOI: 10.1212/wnl.66.10_suppl_4.s24. View

Sawada M, Imamura K, Nagatsu T . Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm Suppl. 2006; (70):373-81. DOI: 10.1007/978-3-211-45295-0_57. View

Mandegary A, Saeedi A, Eftekhari A, Montazeri V, Sharif E . Hepatoprotective effect of silyamarin in individuals chronically exposed to hydrogen sulfide; modulating influence of TNF-α cytokine genetic polymorphism. Daru. 2013; 21(1):28. PMC: 3626872. DOI: 10.1186/2008-2231-21-28. View

Nencini C, Giorgi G, Micheli L . Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine. 2006; 14(2-3):129-35. DOI: 10.1016/j.phymed.2006.02.005. View

Deumens R, Blokland A, Prickaerts J . Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol. 2002; 175(2):303-17. DOI: 10.1006/exnr.2002.7891. View

Haddadi R, Nayebi A, Farajniya S, Brooshghalan S, Sharifi H . Silymarin improved 6-OHDA-induced motor impairment in hemi-parkisonian rats: behavioral and molecular study. Daru. 2014; 22:38. PMC: 4001109. DOI: 10.1186/2008-2231-22-38. View

10.

Lee J, Tran T, Tansey M . Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol. 2009; 4(4):419-29. PMC: 3736976. DOI: 10.1007/s11481-009-9176-0. View

11.

Qin L, Wu X, Block M, Liu Y, Breese G, Hong J . Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007; 55(5):453-62. PMC: 2871685. DOI: 10.1002/glia.20467. View

12.

Mahmoudi J, Mohajjel Nayebi A, Samini M, Reyhani-Rad S, Babapour V . 5-HT(1A) receptor activation improves anti-cataleptic effects of levodopa in 6-hydroxydopamine-lesioned rats. Daru. 2012; 19(5):338-43. PMC: 3304392. View

13.

Warner T, Schapira A . Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol. 2003; 53 Suppl 3:S16-23; discussion S23-5. DOI: 10.1002/ana.10487. View

14.

Gupta O, Sing S, Bani S, Sharma N, Malhotra S, Gupta B . Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000; 7(1):21-4. DOI: 10.1016/S0944-7113(00)80017-3. View

15.

Manna S, Mukhopadhyay A, Van N, Aggarwal B . Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol. 1999; 163(12):6800-9. View

16.

Glinka Y, Gassen M, Youdim M . Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl. 1997; 50:55-66. DOI: 10.1007/978-3-7091-6842-4_7. View

17.

Whishaw I, Whishaw P, Gorny B . The structure of skilled forelimb reaching in the rat: a movement rating scale. J Vis Exp. 2008; (18). PMC: 3253566. DOI: 10.3791/816. View

18.

Sharifi H, Mohajjel Nayebia A, Farajnia S . Dose-Dependent Effect of Flouxetine on 6-OHDA-Induced Catalepsy in Male Rats: A Possible Involvement of 5-HT1A Receptors. Adv Pharm Bull. 2013; 3(1):203-6. PMC: 3846046. DOI: 10.5681/apb.2013.033. View

19.

Carvalho M, Campos F, Coimbra B, Pego J, Rodrigues C, Lima R . Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits. Mol Neurodegener. 2013; 8:14. PMC: 3653696. DOI: 10.1186/1750-1326-8-14. View

20.

Mogi M, Togari A, Tanaka K, Ogawa N, Ichinose H, Nagatsu T . Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction. Neurosci Lett. 1999; 268(2):101-4. DOI: 10.1016/s0304-3940(99)00388-2. View